Format
Sort by

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 52

1.

Exenatide and rare adverse events.

Ahmad SR, Swann J.

N Engl J Med. 2008 May 1;358(18):1970-1; discussion 1971-2. No abstract available.

PMID:
18456920
2.

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.

Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group..

Diabetes Obes Metab. 2008 Sep;10(10):959-69. doi: 10.1111/j.1463-1326.2007.00839.x.

PMID:
18201203
3.

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.

Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M.

Curr Med Res Opin. 2008 Feb;24(2):537-50. doi: 10.1185/030079908X260925 .

PMID:
18194595
4.

Standards of medical care in diabetes--2008.

American Diabetes Association..

Diabetes Care. 2008 Jan;31 Suppl 1:S12-54. doi: 10.2337/dc08-S012. No abstract available.

PMID:
18165335
6.

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG.

Curr Med Res Opin. 2008 Jan;24(1):275-86.

PMID:
18053320
7.

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.

Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP.

Diabetes Res Clin Pract. 2008 Feb;79(2):291-8.

PMID:
17933414
8.

The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.

Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M.

Diabetes Technol Ther. 2007 Aug;9(4):317-26.

PMID:
17705687
9.

Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.

Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O.

Diabetes Care. 2007 Nov;30(11):2794-9.

PMID:
17698615
10.

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

Amori RE, Lau J, Pittas AG.

JAMA. 2007 Jul 11;298(2):194-206. Review.

PMID:
17622601
11.

Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents.

Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG.

Diabetes Care. 2007 Nov;30(11):2767-72.

PMID:
17595353
12.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group..

Diabetes Obes Metab. 2007 Sep;9(5):733-45.

PMID:
17593236
13.

A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.

Barnett A, Allsworth J, Jameson K, Mann R.

Curr Med Res Opin. 2007 Jul;23(7):1493-507. Review.

PMID:
17559747
14.

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.

Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C.

J Clin Endocrinol Metab. 2007 Aug;92(8):2977-83.

PMID:
17504894
15.

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group..

Diabetes Care. 2007 Aug;30(8):1979-87. Erratum in: Diabetes Care. 2008 Aug;31(8):1713.

PMID:
17485570
16.

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.

Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, Gottesdiener K, Wagner J, Herman GA.

Diabetes Care. 2007 Jul;30(7):1862-4. No abstract available.

PMID:
17468348
17.

Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.

Karl D, Philis-Tsimikas A, Darsow T, Lorenzi G, Kellmeyer T, Lutz K, Wang Y, Frias JP.

Diabetes Technol Ther. 2007 Apr;9(2):191-9.

PMID:
17425446
18.

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG.

Ann Intern Med. 2007 Apr 3;146(7):477-85. Erratum in: Ann Intern Med. 2007 Jun 19;146(12):896.

PMID:
17404349
Items per page

Supplemental Content

Support Center